Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Details for Australian Patent Application No. 2004200722 (hide)

Owner Bayer Pharmaceuticals Corporation

Inventors Renick, Joel; Lowinger, Timothy, B; Khire, Uday; Smith, Roger, A; Natero, Reina; Sibley, Robert, N; Monahan, Mary-Katherine; Scott, William, J; Riedl, Bernd; Dumas, Jacques; Wood, Jill, E

Agent Davies Collison Cave

Pub. Number AU-B-2004200722

Parent 25016

Filing date 24 February 2004

Wipo publication date 18 March 2004

Acceptance publication date 10 January 2008

International Classifications

C07D 211/78 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

A61K 31/17 (2006.01) - having the group NC(O)N or NC(S)N, e.g. urea, thiourea, carmustine

A61K 31/33 (2006.01) - Heterocyclic compounds

A61K 31/535 (2006.01) - having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

A61K 31/54 (2006.01) - having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame

C07C 275/20 (2006.01) Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups

C07C 275/22 (2006.01) Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups

C07C 275/24 (2006.01) Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups

C07C 275/28 (2006.01) Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups

C07C 311/29 (2006.01) Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups

C07D 209/48 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 211/72 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 213/75 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D 213/81 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D 295/12 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

C07D 295/18 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

C07D 317/22 (2006.01) Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms

Event Publications

11 March 2004 Complete Application Filed

18 March 2004 Application Open to Public Inspection

  Published as AU-B-2004200722

10 January 2008 Assignment before Grant

  Bayer Corporation The application has been assigned to Bayer Pharmaceuticals Corporation

10 January 2008 Application Accepted

  Published as AU-B-2004200722

8 May 2008 Standard Patent Sealed

2 October 2008 Extension of Term of Standard Patents

  Bayer Pharmaceuticals Corporation The earliest first regulatory approval date provided by the patentee 27 Sep 2006 For the goods NEXAVAR sorabenib tosylate

6 November 2008 Extension of Term of Standard Patents

  Bayer Pharmaceuticals Corporation The earliest first regulatory approval date provided by the patentee 27 Sep 2006 For the goods NEXAVAR sorafenib tosylate Address for service in Australia: Davies Collison Cave 255 Elizabeth Street Sydney NSW 2000

13 November 2008 Corrigenda

  Extensions of Term of Standard Patent, Section 70 - Applications Filed Under the name Bayer Pharmaceuticals Corporation, Application No. 2004200722, correct the pharmaceutical name to read NEXAVAR sorafenib tosylate

26 March 2009 Extension granted

  Bayer Pharmaceuticals Corporation The earliest first regulatory approval date provided by the patentee 27 Sep 2006 For the goods NEXAVAR sorafenib tosylate Extension of Term of patent pursuant to Section 77 expires on 27 Sep 2021

22 October 2009 Assignment Registered

  Bayer Pharmaceuticals Corporation The patent has been assigned to Bayer Healthcare LLC 2004202276 3M Innovative Properties Company The patent has been assigned to Promega Corporation 2004202277 3M Innovative Properties Company The patent has been assigned to Promega Corporation

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004200723-Stationery Item

2004200721-No-spill Drinking Cup Apparatus